Want to see ADGM full AI Analyst Report?
ADGM Stock Chart & Stats
$0.55
>-$0.01(-0.08%)
At close: 4:00 PM EDT
$0.55
>-$0.01(-0.08%)
Day’s Range― - ―
52-Week Range$0.36 - $2.58
Previous Close$0.47
Volume28.41K
Average Volume (3M)16.72M
Market Cap
$11.74M
Enterprise Value$32.73
Total Cash (Recent Filing)$7.74M
Total Debt (Recent Filing)$26.00M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Nov 12, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares Outstanding22,210,459
10 Day Avg. Volume342,433
30 Day Avg. Volume16,717,992
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.39
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside445.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.98
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Validation Of VT Ablation PlatformThe completed pivotal trial and reported clinical outcomes provide meaningful evidence for the vCLAS platform. If sustained through regulatory review and commercialization, this evidence may support physician adoption and differentiate the product in ventricular tachycardia ablation.
Advancing Regulatory And Commercial MilestonesProgress across PMA review, CMS-supported study activity, and planned market introduction indicates movement toward commercialization. Regulatory clearance and reimbursement access would be important prerequisites for converting the technology into future revenue.
Losses Have Improved From Prior PeriodsAlthough Adagio remains deeply unprofitable, the improvement from the much larger 2024 losses suggests some progress in controlling expenses or development spending. Continued discipline could extend runway, though it has not yet produced profitability or revenue.
Bears Say
No Commercial Revenue And Persistent LossesThe absence of revenue confirms that the company remains dependent on successful regulatory clearance and future commercialization. Persistent operating and net losses increase execution risk and leave no demonstrated scalable business model to absorb development costs.
Heavy Cash Burn And External Funding DependenceAdagio is not yet funding operations internally, so continued clinical, regulatory, and commercial work likely requires external capital. This dependence can constrain development flexibility and increase dilution or financing risk before products generate meaningful cash.
Negative Equity And Nasdaq Listing DeficienciesNegative equity and two Nasdaq deficiencies indicate weakened capitalization and limited financial flexibility. Failure to restore equity or satisfy listing requirements could disrupt market access, complicate fundraising, and add substantial uncertainty to the company’s operating plans.
Adagio Medical Holdings News
ADGM FAQ
What was Adagio Medical Holdings’s price range in the past 12 months?
Adagio Medical Holdings lowest stock price was $0.36 and its highest was $2.58 in the past 12 months.
What is Adagio Medical Holdings’s market cap?
Adagio Medical Holdings’s market cap is $11.74M.
When is Adagio Medical Holdings’s upcoming earnings report date?
Adagio Medical Holdings’s upcoming earnings report date is Nov 12, 2026 which is in 71 days.
How were Adagio Medical Holdings’s earnings last quarter?
Adagio Medical Holdings released its earnings results on Aug 11, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.27 by -$0.03.
Is Adagio Medical Holdings overvalued?
According to Wall Street analysts Adagio Medical Holdings’s price is currently Undervalued.
Does Adagio Medical Holdings pay dividends?
Adagio Medical Holdings does not currently pay dividends.
What is Adagio Medical Holdings’s EPS estimate?
Adagio Medical Holdings’s EPS estimate is -0.25.
How many shares outstanding does Adagio Medical Holdings have?
Adagio Medical Holdings has 22,210,459 shares outstanding.
What happened to Adagio Medical Holdings’s price movement after its last earnings report?
Adagio Medical Holdings reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.27. Following the earnings report the stock price went down -3.36%.
Which hedge fund is a major shareholder of Adagio Medical Holdings?
Currently, no hedge funds are holding shares in ADGM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adagio Medical Holdings
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
ADGM Stock 12 Month Forecast
Average Price Target
$3.00
▲(445.45% Upside)
Technical Analysis
Ownership Overview
45.47% Insiders
0.47% Mutual Funds
1.37% Other Institutional Investors
52.19% Public Companies and
Individual Investors